Monotherapies including the agonist of 5-HT2C receptor, lorcaserin, or the protease-resistant long-acting GLP-1, liraglutide, as well as combinational therapies of stimulators of noradrenaline or serotonine-release combined with sympathomimetic anticonvulsant or opiod receptor antagonist are currently approved for treating obesity and T2D, combined with exercise and a balanced diet [14,15,293]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.